Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An announcement from Disc Medicine ( (IRON) ) is now available.
Disc Medicine, a biopharmaceutical company, unveiled promising interim results from its Phase 1b trial of DISC-0974 at the ASN Kidney Week 2024. The study showcased significant improvements in anemia markers for patients with non-dialysis-dependent chronic kidney disease (NDD-CKD), demonstrating substantial reductions in hepcidin levels and increases in hemoglobin. DISC-0974’s safety and tolerability were confirmed, highlighting its potential as a treatment for anemia linked to various chronic conditions. These findings suggest DISC-0974’s broader applicability in addressing anemia associated with inflammatory diseases.
For detailed information about IRON stock, go to TipRanks’ Stock Analysis page.
